Persistent bothersome urinary frequency following stereotactic body radiation therapy for clinically localized prostate cancer: rationale for prophylactic β3-agonist in men with elevated baseline international prostate symptom scores
Bothersome post-SBRT urinary frequency persists 1-month post-SBRT. Baseline LUTS predicts bothersome post-treatment urinary frequency. Prophylactic alpha-adrenergic antagonists do not protect against bothersome acute urinary frequency. This paper makes the case that urinary frequency may be better addressed with a prophylactic beta-3 agonist, like vibegron, which is designed to treat storage-related LUTS concerns.
Authors
- Deepak Kumar (ORCID: https://orcid.org/0000-0003-0234-3165)
- Malika Danner
- Ryan Andrew Hankins (ORCID: https://orcid.org/0000-0001-5586-0102)
- Simeng Suy
- A. Zwart
- Min Ji Koh (ORCID: https://orcid.org/0009-0004-1950-3860)
- Kelly Gaudian
- Jennifer Zack (ORCID: https://orcid.org/0000-0001-5357-7223)
- Sean Collins
- Emily Lindbloom
- Timothy O’Connor
Institutions
- North Carolina Central University (US)
- Georgetown University (US)
- University of South Florida (US)
- Georgetown Hospital (CA)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-15
- DOI
- https://doi.org/10.3389/fonc.2025.1642614
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute on Minority Health and Health Disparities